Price (delayed)
$23.95
Market cap
$3.45B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$3.41B
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing
There are no recent dividends present for DNLI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.